Skip to main content

PerkinElmer Q4 Revenues Jump 11 Percent on Strong Gene-Screening Business Growth

NEW YORK, Jan. 27 (GenomeWeb News) - Spurred by revenue in its Life and Analytical Sciences division, PerkinElmer's total receipts jumped 11 percent in the fourth quarter of 2004.

 

Total company revenue for the three months ended Dec. 31 shot up to $478 million from $431.8 million in the year-ago period. The Life and Analytical Sciences division saw revenue grow to $311 million in the fourth qurter of 2004 from $290 million in the same period last year -- a rise of 6.8 percent.

 

The company attributed the division's growth during the quarter to "double digit" revenue growth in its genetic-screening, -service and environmental businesses.

 

PerkinElmer's R&D expenses for the fourth quarter of 2004 were up $4.7 million to $23.6 million.

 

Net income grew 27 percent, as PerkinElmer reported $37.9 million for the fourth quarter of 2004, compared to $27.9 million year-over-year.

 

PerkinElmer had around $197.5 million in cash and equivalents as of Jan. 2.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.